Edwards Lifesciences Corporation
—- Market cap
- —
- Debt
- —
- Cash
- −$2.94B
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: EW stock price vs PFE: inconclusive — current versus $37.21 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at PFE's multiple
Implied fair value · at EW's multiple
Needs EW P/E.
Snapshot Sep 10, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
11 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 71% equity / 29% debt · EV / Revenue 3.54x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Edwards Lifesciences Corporation · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
PFIZER INC · implied price per share
Bear
$12.82
Base
$16.23
Bull
$22.30
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
ABBOTT LABORATORIES
EW vs ABT
JOHNSON & JOHNSON
EW vs JNJ
Medtronic plc
EW vs MDT
BOSTON SCIENTIFIC CORP
EW vs BSX
BAXTER INTERNATIONAL INC
EW vs BAX
DENTSPLY SIRONA Inc.
EW vs XRAY
Merck & Co., Inc.
EW vs MRK
AbbVie Inc.
EW vs ABBV
BRISTOL MYERS SQUIBB CO
EW vs BMY
ELI LILLY & Co
EW vs LLY
AMGEN INC
EW vs AMGN
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe EW can sustain double-digit revenue growth and preserve its high margins, then hold only selectively or wait for a cheaper entry because the current valuation is far above PFE and the model-implied price is materially lower than today’s price.
EW trades at a large premium to PFE across earnings, sales, and EBITDA-based valuation metrics, despite a modeled implied price far below the current share price. The valuation gap is driven by EW’s much higher P/E, P/S, EV/EBITDA, and EV/Revenue multiples, while PFE remains cheaper on all of those measures.
Supporting Metrics